FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
FibroBiologics (Nasdaq: FBLG) has filed a patent application for generating three-dimensional hemopoietic organoids using fibroblast cell-based technology. This method could potentially produce therapeutic organoids capable of giving rise to various immune cells, including T cells, B cells, NK cells, and CAR-T cells. The process is described as rapid, cost-effective, and scalable, with organoids ready for transplantation within three days or cryopreserved for later use.
Dr. Hamid Khoja, Chief Scientific Officer, highlighted the potential for these organoids to be transplanted into living organisms to generate functional immune cells. CEO Pete O'Heeron emphasized that this patent, if issued, could allow FibroBiologics to develop a versatile solution for in vivo immune cell generation, potentially revolutionizing regenerative medicine and cancer immunotherapy.
FibroBiologics (Nasdaq: FBLG) ha presentato una domanda di brevetto per la generazione di organoidi ematopoietici tridimensionali utilizzando una tecnologia basata su cellule fibroblastiche. Questo metodo potrebbe potenzialmente produrre organoidi terapeutici in grado di dare origine a diverse cellule immunitarie, comprese le cellule T, le cellule B, le cellule NK e le cellule CAR-T. Il processo è descritto come rapido, economico e scalabile, con organoidi pronti per il trapianto entro tre giorni o criopreservati per un uso successivo.
Dr. Hamid Khoja, Chief Scientific Officer, ha sottolineato il potenziale di questi organoidi per essere trapiantati in organismi viventi al fine di generare cellule immunitarie funzionali. Il CEO Pete O'Heeron ha enfatizzato che questo brevetto, se concesso, potrebbe consentire a FibroBiologics di sviluppare una soluzione versatile per la generazione in vivo di cellule immunitarie, potenzialmente rivoluzionando la medicina rigenerativa e l'immunoterapia anti-cancro.
FibroBiologics (Nasdaq: FBLG) ha presentado una solicitud de patente para generar organoides hematopoyéticos tridimensionales utilizando tecnología basada en células fibroblásticas. Este método podría producir organoides terapéuticos capaces de dar lugar a diversas células inmunitarias, incluidas células T, células B, células NK y células CAR-T. El proceso se describe como rápido, rentable y escalable, con organoides listos para el trasplante en tres días o criopreservados para su uso posterior.
El Dr. Hamid Khoja, Director Científico, destacó el potencial de estos organoides para ser trasplantados en organismos vivos para generar células inmunitarias funcionales. El CEO Pete O'Heeron enfatizó que esta patente, si se concede, podría permitir a FibroBiologics desarrollar una solución versátil para la generación de células inmunitarias in vivo, revolucionando potencialmente la medicina regenerativa y la inmunoterapia contra el cáncer.
FibroBiologics (Nasdaq: FBLG)는 섬유아세포 기반 기술을 사용하여 3차원 조혈 오르가노이드를 생성하기 위한 특허 출원을 했습니다. 이 방법은 T 세포, B 세포, NK 세포 및 CAR-T 세포를 포함한 다양한 면역 세포로 이어질 수 있는 치료용 오르가노이드를 생산할 가능성이 있습니다. 이 과정은 신속하고 비용 효율적이며 확장 가능한 것으로 설명되며, 오르가노이드는 3일 이내에 이식 준비가 완료되거나 나중에 사용할 수 있도록 냉동 보존됩니다.
책임 과학자인 Hamid Khoja 박사는 이러한 오르가노이드를 생명체에 이식하여 기능적인 면역 세포를 생성할 수 있는 가능성을 강조했습니다. CEO인 Pete O'Heeron은 이 특허가 발급될 경우 FibroBiologics가 in vivo 면역 세포 생성을 위한 다재다능한 솔루션을 개발할 수 있게 될 것이며, 이는 재생 의학 및 암 면역 요법에 혁신을 가져올 수 있다고 강조했습니다.
FibroBiologics (Nasdaq: FBLG) a déposé une demande de brevet pour la génération de organoïdes hématopoïétiques tridimensionnels utilisant la technologie basée sur les cellules fibroblastiques. Cette méthode pourrait potentiellement produire des organoïdes thérapeutiques capables de donner naissance à diverses cellules immunitaires, y compris des cellules T, des cellules B, des cellules NK et des cellules CAR-T. Le processus est décrit comme rapide, économique et évolutif, avec des organoïdes prêts pour la transplantation dans les trois jours ou cryopréservés pour une utilisation ultérieure.
Le Dr Hamid Khoja, directeur scientifique, a souligné le potentiel de ces organoïdes à être transplantés dans des organismes vivants pour générer des cellules immunitaires fonctionnelles. Le PDG Pete O'Heeron a souligné que ce brevet, s'il est accordé, pourrait permettre à FibroBiologics de développer une solution polyvalente pour la génération de cellules immunitaires in vivo, pouvant potentiellement révolutionner la médecine régénérative et l'immunothérapie contre le cancer.
FibroBiologics (Nasdaq: FBLG) hat einen Patentantrag zur Erzeugung von drei-dimensionalen hämatopoietischen Organoiden eingereicht, der auf fibroblastischer Zelltechnologie basiert. Dieses Verfahren könnte potenziell therapeutische Organoide hervorrufen, die in der Lage sind, verschiedene Immunzellen, einschließlich T-Zellen, B-Zellen, NK-Zellen und CAR-T-Zellen, zu erzeugen. Der Prozess wird als schnell, kosteneffektiv und skalierbar beschrieben, wobei die Organoide innerhalb von drei Tagen zur Transplantation bereit sind oder für eine spätere Verwendung kryokonserviert werden können.
Dr. Hamid Khoja, Chief Scientific Officer, hob das Potenzial dieser Organoide hervor, in lebende Organismen transplantiert zu werden, um funktionale Immunzellen zu erzeugen. CEO Pete O'Heeron betonte, dass dieses Patent, wenn es erteilt wird, FibroBiologics ermöglichen könnte, eine flexible Lösung zur in vivo-Erzeugung von Immunzellen zu entwickeln, was potenziell eine Revolution in der regenerativen Medizin und der Krebsimmuntherapie darstellen könnte.
- Filing of a patent application for novel three-dimensional hemopoietic organoid technology
- Potential for rapid, cost-effective, and scalable production of therapeutic organoids
- Organoids can be ready for transplantation within three days or cryopreserved
- Technology could revolutionize regenerative medicine and cancer immunotherapy
- None.
Insights
This patent application represents a significant advancement in regenerative medicine and immunotherapy. The ability to generate three-dimensional hemopoietic organoids capable of producing various immune cells could revolutionize treatments for immune disorders and cancer.
The potential for rapid production (within three days) and cryopreservation offers flexibility in clinical applications. This technology could address challenges in cell therapy manufacturing, potentially reducing costs and improving accessibility.
However, it's important to note that this is a patent application, not an approved patent. The path from patent to marketable product is long and uncertain. Investors should monitor progress in preclinical and clinical studies to assess the technology's real-world viability and potential market impact.
FibroBiologics' patent application could significantly expand its intellectual property portfolio, potentially strengthening its market position. With 160+ patents issued and pending, the company is building a robust IP foundation in fibroblast-based therapeutics.
However, the financial impact remains speculative. The technology's commercial viability depends on successful development, regulatory approvals and market adoption. Investors should consider that R&D costs may increase as the company pursues this new avenue, potentially impacting short-term financials.
While promising, it's important to remember that many biotech innovations fail to reach the market. Investors should balance the potential long-term upside with the inherent risks in early-stage biotech development.
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells.
The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cells. This includes cells such as T cells, B cells, NK cells, macrophages, monocytes, neutrophils, platelets, red blood cells, myeloid-derived suppressor cells, mast cells, eosinophils, basophils, dendritic cells, and CAR-T cells.
“This method potentially offers a rapid, cost-effective, and scalable way to produce therapeutic hemopoietic organoids, which can be transplanted into a living organism to generate desired functional immune cells,” commented Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D. “Additionally, the three-dimensional organoids can be ready for immediate transplantation into a subject within three days of culture or cryopreserved for later use.”
“Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our platform,” commented Founder & CEO of FibroBiologics, Pete O’Heeron. “This patent, if issued, will allow us to pursue the development of a versatile, scalable solution for generating immune cells in vivo that could revolutionize regenerative medicine and cancer immunotherapy.”
For more information, please visit FibroBiologics' website or email FibroBiologics at info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential to produce therapeutic hemopoietic organoids and to generate desired functional immune cells, the speed of transplantation, and FibroBiologics’ ability to pursue the development of a solution for generating immune cells that could revolutionize regenerative medicine and cancer immunotherapy. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the new patent application filed by FibroBiologics (FBLG) about?
How quickly can the organoids developed by FibroBiologics (FBLG) be ready for transplantation?
What potential applications does FibroBiologics (FBLG) see for their new organoid technology?
What types of immune cells can the organoids developed by FibroBiologics (FBLG) potentially produce?
